AUTHORS
Zhiming Li, MD, Peng SUN, PhD2, Panpan LIU3, Hang Yang4, Yu Wang5, Hui Zhou6, Chan Long7
AFFILIATIONS
1 Sun Yat-Sen University Cancer Center, Guangzhou, China
2 Sun Yat-Sen University Cancer Center, Guangzhou, China
3 Sun Yat-Sen University Cancer Center, Guangzhou, China
4 Sun Yat-Sen University Cancer Center, Guangzhou, China
5 Sun Yat-Sen University Cancer Center, Guangzhou, China
6 Hunan provincial cancer hospital, Hunan, China
7 Hui Zhou First Hospital, Huizhou, China
ABSTRACT
Background
BTK inhibitors (BTKi) have demonstrated durable efficacy and favorable safety profiles in marginal zone lymphoma (MZL). Orelabrutinib, the first BTKi approved in China, offers enhanced selectivity and improved safety characteristics. Zuberitamab, a novel anti-CD20 monoclonal antibody, potentiates antibody-dependent cellular cytotoxicity (ADCC) and demonstrates synergistic activity with BTK inhibition. This phase II ZOOM trial investigated the combination of orelabrutinib and zuberitamab as a frontline therapeutic strategy for treatment-naive MZL.
Methods
Treatment-naive patients with MZL, aged 18–70 years, were enrolled from 3 centers in China. The study comprised an induction phase of 6 cycles (28-day cycles) with orelabrutinib 150 mg administered daily plus zuberitamab administered intravenously on day 1 of each cycle. Maintenance therapy consisted of orelabrutinib (every cycle) plus zanubrutinib (every 2 cycles) for up to 6 cycles or until treatment discontinuation. The primary endpoint was the complete response (CR) rate assessed by Lugano 2014 criteria at end of treatment (EOT). Key secondary endpoints included undetectable minimal residual disease (uMRD) by next-generation sequencing (NGS), 24-month progression-free survival (PFS24), 24-month overall survival (OS24), and safety profile.
Results
As of July 27, 2026, 33 patients were enrolled, with 31 evaluable for efficacy. The median age was 59 years (interquartile range 49–64), with 60.6% male predominance. Disease characteristics included Ann Arbor stage III–IV in 84.2% of patients, MZLIPI score 2–3 in 53.6%, and Ki67 ≥20% in 30.3%. Among the 31 EOT-evaluable patients, the overall response rate (ORR) was 93.5% (29/31), with CR achieved in 67.7% (21/31) and partial response (PR) in 25.8% (8/31). When stratified by histologic subtype, the CR rate was highest in nodal MZL (NMZL) at 100% and lowest in MALT lymphoma at 63.6%, with no significant differences in progression-free survival (PFS) across subtypes. With a median follow-up of 12.3 months, the median duration of response (DOR), PFS, and overall survival (OS) have not been reached. The 12-month PFS was 97%, and 24-month PFS was 90.9%. PFS rates at 12 months were 95.7% for MALT lymphoma, 100% for splenic MZL (SMZL), and 100% for SMZL, respectively. OS rates at 12 months and 24 months were both 97%. Regarding MRD assessment, uMRD was achieved in 84.2% of patients from baseline through cycle 6, and the uMRD negativity rate from baseline through cycle 12 was 85.7%. Any-grade adverse events (AEs) occurred in 69.7% of patients (23/33), while grade ≥3 AEs were observed in 45.5% (15/33), including neutropenia in 18.2% and grade 3 pneumonia in 15.1% of patients.
Conclusion
The combination of orelabrutinib with zuberitamab achieves high efficacy, induces deep and durable responses, and demonstrates favorable tolerability in previously untreated MZL. This regimen represents a promising frontline therapeutic option for patients with MZL.
ClinicalTrials.gov ID: NCT06985472
DISCLOSURES
Zhiming Li, MD: No relevant conflicts of interest to declare.